BMBL is being acquired by Ithaca Holdings in an all-cash take-private deal at $6.05 per share, valuing the dating-app operator at roughly $1.3 billion. MNDR is a Singapore-based, micro-cap AI health platform pivoting into AI data centers, with extreme price volatility across recent sessions.
MNDR is down -46.05% to about $1.64 during regular trading, giving back a large chunk of the previous session's +257.65% surge from $0.85 to $3.04. The decline is a sharp mean-reversion/profit-taking reversal, not driven by any new company-specific news or filing.
MNDR is down -25.33% to roughly $2.27 in regular trading, versus a prior session close of $3.04. The drop is a sharp reversal after Monday's +257.65% surge, which closed at $3.04 on an intraday spike to $5.67 and roughly 74.8M shares traded.
MNDR soared roughly +297.65% during Monday's regular session to about $3.38, extending a premarket gap-up of around +150% from Friday's $0.85 close. The surge is a micro-cap momentum/squeeze move rather than a same-day fundamental event, amplified by a tiny float of only about 398K shares following its June 1-for-6 reverse split.
MNDR is down -39.47% to roughly $0.92 in regular trading, reversing the prior session's close of $1.52. The decline unwinds October 7's +25.6% surge, which came on about 2.2M shares traded versus a ~185K average — classic low-float, micro-cap volatility.
WORX closed up +30.63% (+$1.70) to $7.25 in regular Nasdaq trading, off a prior close of $5.55. Primary catalyst: SCWorx resumed Nasdaq trading after the Hearings Panel reversed its delisting decision and approved continued listing.
WORX is SCWorx Corp., a healthcare data-management provider with a market capitalization of roughly $3 million. The $14 target is not an analyst consensus; no sell-side analysts currently publish price targets for WORX, so this figure is a fallback valuation objective drawn from publicly discussed estimates.
AI-enabled data platform: SCWorx is layering artificial intelligence (AI) onto its proprietary healthcare supply chain data assets, which management believes could improve scalability and gross margins. Listing restoration: A reinstated Nasdaq listing removes a key overhang and could broaden institutional and retail investor access, though execution remains unproven.
TEM is trading down -8.99% to about $76.04 during regular market hours, erasing Monday's +9.03% surge that followed FDA 510(k) clearance for its ECG-MR AI tool. The decline is driven by continued large-scale insider selling: CEO Eric Lefkofsky has sold over 1 million Class A shares since mid-September, at prices between roughly $76 and $81.
Different ends of the spectrum: BEAT is a pre-revenue, micro-cap medical device developer, while MDT is a diversified, dividend-paying global healthcare technology leader. Recent catalysts diverge: BEAT's recent momentum has been driven by an FDA (U.S. Food and Drug Administration) Breakthrough Device Designation, whereas MDT's story centers on durable organic growth and raised guidance.
BEAT jumped roughly +60% to about $0.69 during Monday's regular session, up from Friday's $0.43 close. Primary catalyst: the FDA granted Breakthrough Device Designation for HeartBeam's at-home 3D ECG heart attack assessment system.
The $3.50 central target is the arithmetic mean of five verified analyst price targets, which range widely from $2.00 to $5.00. With shares near $0.43, reaching $3.50 would require a gain of roughly 714%, a very large move.
BEAT is up +69.77% during Monday's regular session, trading around $0.73 versus Friday's roughly $0.43 close, after spiking as much as ~90% intraday. The primary catalyst: the FDA granted Breakthrough Device Designation for HeartBeam's at-home heart attack assessment tool built on its 3D ECG platform.
Strategic pivot underway: HeartBeam is shifting from direct medical-device sales toward licensing its proprietary 3D ECG (electrocardiogram) signal platform to established distribution partners, a move aimed at faster global adoption with a leaner cost structure. Major clinical catalyst: Expanding beyond arrhythmia assessment into heart attack detection represents the company's largest addressable-market opportunity and a central focus of its near-term evidence-building efforts.
Two different instruments, one company: ONMD is OneMedNet Corporation's common stock, while ONMDW is a derivative warrant tied to the same underlying business. Distinct risk profiles: The common stock reflects the operating company directly, whereas the warrant adds leverage, time-decay, and exercise-price sensitivity on top of business fundamentals.
HNGE shares have climbed roughly 9% over the trailing 30 days, holding near 52-week highs after a powerful 2026 run. Second-quarter 2026 revenue rose 53% year over year to $213 million, while operating margin expanded to 29% from 19%.
Schrödinger (SDGR) closed near $29.45 after a powerful rally that took shares roughly 140% higher over six months and pushed the stock to fresh 52-week highs. The $40 stock price target represents a meaningful move of roughly 35% above recent levels and sits well above the stock's current 52-week high near $31.59.
Schrödinger (SDGR) shares rose roughly 71% over the 30 days ending September 17, 2026, climbing from about $17.67 to $30.24 and reaching a new 52-week high. The rally reflects growing investor enthusiasm for AI-driven drug discovery, the launch of the Bunsen AI co-scientist, and the formation of Tectora Therapeutics.
TEM is up +10.36% during regular trading hours, trading near $77.22 versus a $69.97 prior close. Primary catalyst: Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56.
Tempus AI (TEM) climbed roughly 35.5% over the trailing 30 days, from about $51.64 to $69.97 on a closing basis. The advance was amplified by a technical short squeeze tied to positive third-party precision-medicine news and an expanded AI collaboration with Merck.